Caballero-Marcos, AranzazuSalcedo, MagdalenaAlonso-Fernandez, RobertoRodriguez-Peralvarez, ManuelOlmedo, MariaGraus Morales, JavierCuervas-Mons, ValentinCachero, AlbaLoinaz-Segurola, CarmeloIñarrairaegui, MercedesCastells, LluisPascual, SoniaVinaixa-Aunes, CarmenGonzalez-Grande, RocioOtero, AlejandraTome, SantiagoTejedor-Tejada, JavierAlamo-Martinez, Jose MariaGonzalez-Dieguez, LuisaNogueras-Lopez, FlorBlanco-Fernandez, GerardoMuñoz-Bartolo, GemaBustamante, Francisco JavierFabrega, EmilioRomero-Cristobal, MarioMartin-Mateos, RosaDel Rio-Izquierdo, JuliaArias-Milla, AnaCalatayud, LauraMarcacuzco-Quinto, Alberto AFernandez-Alonso, VictorGomez-Gavara, ConcepcionColmenero, JordiMuñoz, PatriciaPons, Jose A2023-02-092023-02-092021-03-29Caballero-Marcos A, Salcedo M, Alonso-Fernández R, Rodríguez-Perálvarez M, Olmedo M, Graus Morales J, et al. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. Am J Transplant. 2021 Aug;21(8):2876-2884http://hdl.handle.net/10668/17554The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case-control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17–83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03–1.36), and therapy with renin–angiotensin–aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47–34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline.enClinical research/practiceImmune regulationImmunosuppressantImmunosuppression/immune modulationInfection and infectious agents-viralInfectious diseaseLiver transplantation/hepatologyCOVID-19FemaleHumansImmunity, humoralLiver transplantationProspective studiesSARS-CoV-2Transplant recipientsresearch article33835707open accessEstudios prospectivosInmunidad humoralReceptores de trasplantesTrasplante de hígado10.1111/ajt.165991600-6143PMC8251470https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251470https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251470/pdf